THERMO FISHER SCIENTIFIC HOOKS QIAGEN IN $11.5 BILLION DEAL
Important Update: Thermo Fisher Scientific (NYSE: TMO) has terminated the acquisition agreement with QIAGEN (NYSE: QGEN). QIAGEN will pay to Thermo Fisher Scientific an expense reimbursement payment of $95 million in cash in accordance with the terms of the acquisition agreement between the two companies. Read the details of this failed landmark acquisition here and get the strategic insights on how the $11.5 billion deal initially transpired in the story below:
Thermo Fisher Scientific advances further into genetic testing
A global company with a bio scientific focus
Thermo Fisher Scientific (NYSE: TMO) moves deeper into the genetic testing market sector with its purchase of Qiagen. Qiagen (NYSE: QGEN) specializes in sample and assay technologies used in academic and pharmaceutical research, applied testing, molecular diagnostics, oncology plus other clinical and scientific applications.
Qiagen shareholders net a decent premium on the deal
With its official main base in Venlo, Limburg, Netherlands but primary operating headquarters in Hilden, Germany, Qiagen generates just under $1.2 billion in annual sales. Stockholders reportedly will receive a 23% premium. As a timely coincidence to world events, Qiagen has a coronavirus virus test on the market that it is selling to China.
Thermo Fisher Scientific continues to build its advanced global bioscience business
TFS is a healthcare conglomerate with substantial lines of clinical disposables, diagnostic equipment, laboratory instrumentation, reagents, software plus medical research technology solutions and services. TFS is a respected competitor and very well known to its academic, government, healthcare provider organization, life science and pharmaceutical clients.
Primary rivals to Thermo Fisher Scientific in core as well as genetic research lines include:
- Abbott
- Agilent Technologies
- BGI Group
- Bruker
- Danaher
- Eurofins Scientific
- Harvard Bioscience
- Illumina
- Macrogen
- PerkinElmer
- PierianDx
- Roche
A successful healthcare leader with multiple capabilities
Founded in 1956, TFS is based in Waltham, MA and generates over $25 billion in annual sales. They operate various business units and divisions, these are the main ones:
- Applied Biosystems
- Fisher Scientific
- Invitrogen
- Thermo Scientific
- Unity Lab Services
While TFS may choose to keep Qiagen as a separate business unit, its product lines align well with the TFS’ Applied Biosystems business unit and may be integrated into the unit to minimize redundancies.
Thank you for reading this story
Read my other articles about medical and healthcare business trends, content marketing and digital strategy, brand and product management, consumer wellness, managed care and market access strategy. Contact me today for your healthcare content writing and content strategy needs for medical, business, academic, patient and consumer healthcare audiences.
I have over 20 years of experience in the healthcare industry producing valuable healthcare content for audiences and customers spanning physicians, nurses, pharmacists plus pharmaceutical companies, medical technology manufacturers, healthcare provider organizations, managed care, investors, consumers and other stakeholders.
Visit and connect…
As a healthcare content writer, my work aligns with an organization’s voice, brand, SEO elements, marketplace and objectives. It establishes trust in their company and recognized value in its products and services that generates revenue.
This experience was earned through working at Walgreens, Pfizer, AbelsonTaylor, TAP (Takeda Abbott Partnership), Hospira Worldwide and Boston Software Systems.
To a large degree, my professional interests emulate my family which includes doctors, nurses, physician assistants and other clinicians plus those that are working in healthcare administration and commercial enterprises.
